Prostate MRI: can we do without DCE sequences in 2013?

Multiparametric MRI (mp-MRI) of the prostate currently provides stable and reproducible performances. The usefulness of dynamic contrast-enhanced (DCE) sequences is currently challenged, as they sometimes only confirm what has already been observed on diffusion-weighted imaging (DWI) and require the additional purchase of a contrast agent. Eliminating these sequences may help accelerate the use of MRI in addition to, or in lieu of, prostate biopsies in selected patients. However, many studies show that these sequences can detect lesions invisible on T2-weighted and diffusion-weighted images, better assess cancer extension and aggressiveness, and finally help detecting recurrence after treatment. We present the various applications of dynamic MRI and discuss the possible consequences of its omission from the current protocol.

[1]  S. Mendrinos,et al.  Prostate cancer foci detected on multiparametric magnetic resonance imaging are histologically distinct from those not detected. , 2012, The Journal of urology.

[2]  L. Lemaitre,et al.  Prostate cancer computer-assisted diagnosis software using dynamic contrast-enhanced MRI , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[3]  H. Kauczor,et al.  Impact of stroma on the growth, microcirculation, and metabolism of experimental prostate tumors. , 2007, Neoplasia.

[4]  D A Bluemke,et al.  Tumor angiogenesis: tutorial on implications for imaging. , 1997, Radiology.

[5]  J E Husband,et al.  The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma. , 1996, Clinical radiology.

[6]  D. Dearnaley,et al.  Dynamic contrast-enhanced MRI for prostate cancer localization. , 2009, The British journal of radiology.

[7]  H. Schlemmer,et al.  Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? , 2004, European Radiology.

[8]  M. Sumura,et al.  Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer , 2008, Acta radiologica.

[9]  P. Grenier,et al.  Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: results from a prospective study. , 2013, Urologic oncology.

[10]  M. Brawer,et al.  Comparison of microscopic vascularity in benign and malignant prostate tissue. , 1993, Human pathology.

[11]  U. A. van der Heide,et al.  Difficulties and potential of correlating local recurrences in prostate cancer with the delivered local dose. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  Silvia D. Chang,et al.  Combined diffusion‐weighted and dynamic contrast‐enhanced MRI for prostate cancer diagnosis—Correlation with biopsy and histopathology , 2006, Journal of magnetic resonance imaging : JMRI.

[13]  François Cornud,et al.  Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imaging , 2011, BJU international.

[14]  B. K. Park,et al.  Prostate MR imaging at 3T using a phased-arrayed coil in predicting locally recurrent prostate cancer after radiation therapy: preliminary experience , 2010, Abdominal Imaging.

[15]  J. Battermann,et al.  Focal salvage guided by T2-weighted and dynamic contrast-enhanced magnetic resonance imaging for prostate cancer recurrences. , 2010, International journal of radiation oncology, biology, physics.

[16]  I. Floriani,et al.  Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. , 2008, AJR. American journal of roentgenology.

[17]  T. Sone,et al.  Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4-10 ng/mL: diagnostic efficacy of diffusion-weighted imaging, dynamic contrast-enhanced MRI, and T2-weighted imaging. , 2011, AJR. American journal of roentgenology.

[18]  Peter Nordbeck,et al.  Minimizing Risk of Nephrogenic systemic fibrosis in Cardiovascular Magnetic Resonance , 2012, Journal of Cardiovascular Magnetic Resonance.

[19]  D. Kuban,et al.  Use of maximum slope images generated from dynamic contrast-enhanced MRI to detect locally recurrent prostate carcinoma after prostatectomy: a practical approach. , 2012, AJR. American journal of roentgenology.

[20]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[21]  D. Portalez,et al.  IRM et bilan d’extension du cancer de la prostate , 2006 .

[22]  J Alfred Witjes,et al.  Staging prostate cancer with dynamic contrast-enhanced endorectal MR imaging prior to radical prostatectomy: experienced versus less experienced readers. , 2005, Radiology.

[23]  Jonathan A. Coleman,et al.  Focal Treatment of Prostate Cancer with Vascular-Targeted Photodynamic Therapy , 2008, TheScientificWorldJournal.

[24]  L. Martí-Bonmatí,et al.  Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study) , 2012, European Radiology.

[25]  村本 聡.  Differentiation of prostate cancer from benign prostate hypertrophy using dual-echo dynamic contrast MR imaging , 2002 .

[26]  N. Sadato,et al.  Differentiation of prostate cancer from benign prostate hypertrophy using dual-echo dynamic contrast MR imaging. , 2002, European journal of radiology.

[27]  Karin Haustermans,et al.  Evaluation of semi-quantitative dynamic contrast-enhanced MRI parameters for prostate cancer in correlation to whole-mount histopathology. , 2012, European journal of radiology.

[28]  T Okada,et al.  Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. , 2001, Urology.

[29]  J. Klasen,et al.  Inter-Reader Agreement of Multi-Parametric MR Imaging for the Detection of Prostate Cancer: Evaluation of a Scoring System , 2012, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

[30]  A. Oto,et al.  Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. , 2011, AJR. American journal of roentgenology.

[31]  T. Sone,et al.  Prostate Cancer Detection in Patients With Total Serum Prostate-Specific Antigen Levels of 4 – 10 ng / mL : Diagnostic Efficacy of Diffusion-Weighted Imaging , Dynamic Contrast-Enhanced MRI , and T 2-Weighted Imaging , 2011 .

[32]  Xavier Leroy,et al.  Dynamic contrast-enhanced-magnetic resonance imaging evaluation of intraprostatic prostate cancer: correlation with radical prostatectomy specimens. , 2009, Urology.

[33]  A. Cesinaro,et al.  [Magnetic resonance with endorectal coil in the local staging of prostatic carcinoma. Comparison with histologic macrosections in 40 cases]. , 1999, La Radiologia medica.

[34]  A R Padhani,et al.  Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies. , 2001, Clinical radiology.

[35]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[36]  Z. Hall.  Cancer , 1906, The Hospital.

[37]  R. Popert,et al.  Does body‐coil magnetic‐resonance imaging have a role in the preoperative staging of patients with clinically localized prostate cancer? , 2004, BJU international.

[38]  Hugh J. Lavery,et al.  Endorectal magnetic resonance imaging has limited clinical ability to preoperatively predict pT3 prostate cancer , 2011, BJU international.

[39]  C. Kim,et al.  Localization of Prostate Cancer Using 3T MRI: Comparison of T2-Weighted and Dynamic Contrast-Enhanced Imaging , 2006, Journal of computer assisted tomography.

[40]  Masoom A Haider,et al.  Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[41]  M. Fiorentino,et al.  Accuracy of endorectal Magnetic Resonance Imaging (MRI) and Dynamic Contrast Enhanced-MRI (DCE-MRI) in the preoperative local staging of prostate cancer , 2012, Urologia.

[42]  H. Shinmoto,et al.  Prostate cancer screening: The clinical value of diffusion‐weighted imaging and dynamic MR imaging in combination with T2‐weighted imaging , 2007, Journal of magnetic resonance imaging : JMRI.

[43]  P. Tan,et al.  Phased-array magnetic resonance imaging of the prostate with correlation to radical prostatectomy specimens: local experience. , 2004, Asian journal of surgery.

[44]  R. Lenkinski,et al.  Dynamic contrast-enhanced MR imaging in the evaluation of patients with prostate cancer. , 2009, Magnetic resonance imaging clinics of North America.

[45]  P Puech,et al.  Detecting prostate cancer with MRI - why and how. , 2012, Diagnostic and interventional imaging.

[46]  A. Renshaw,et al.  Quantifying the impact of seminal vesicle invasion identified using endorectal magnetic resonance imaging on PSA outcome after radiation therapy for patients with clinically localized prostate cancer. , 2004, International journal of radiation oncology, biology, physics.

[47]  Olivier Rouvière,et al.  Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable? , 2007, European Radiology.

[48]  L. Turnbull,et al.  Description of magnetic resonance imaging‐derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions , 2009, BJU international.

[49]  F. Beuvon,et al.  Multiparametric MRI is helpful to predict tumor focality, stage, and size in patients diagnosed with unilateral low-risk prostate cancer , 2011, Prostate Cancer and Prostatic Diseases.

[50]  D. Cosgrove,et al.  Angiogenesis imaging in the management of prostate cancer , 2005, Nature Clinical Practice Urology.

[51]  [Quantitative dynamic MRI and localisation of non-palpable prostate cancer]. , 2009, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[52]  C. Catalano,et al.  Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). , 2012, European journal of radiology.

[53]  Robert E Lenkinski,et al.  Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging--initial results. , 2007, Radiology.

[54]  Janet E. Husband,et al.  The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma , 1995 .

[55]  M. Brawer,et al.  Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity , 1994, Cancer.

[56]  J R Thornbury,et al.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results. , 1997, Radiology.

[57]  Clare Allen,et al.  Dynamic contrast enhanced MRI in prostate cancer. , 2007, European journal of radiology.

[58]  B. Bloch,et al.  Prediction of prostate cancer extracapsular extension with high spatial resolution dynamic contrast-enhanced 3-T MRI , 2012, European Radiology.

[59]  Nacim Betrouni,et al.  Computer-assisted diagnosis of prostate cancer using DCE-MRI data: design, implementation and preliminary results , 2008, International Journal of Computer Assisted Radiology and Surgery.

[60]  A. Villers,et al.  Imaging of organ-confined prostate cancer: functional ultrasound, MRI and PET/computed tomography , 2009, Current opinion in urology.

[61]  S. Palazzo,et al.  Role of imaging and biopsy to assess local recurrence after definitive treatment for prostate carcinoma (surgery, radiotherapy, cryotherapy, HIFU) , 2011, World Journal of Urology.

[62]  Henning Salz,et al.  Dynamic MRI and CAD vs. Choline MRS: Where is the detection level for a lesion characterisation in prostate cancer? , 2009, International journal of radiation biology.

[63]  Kazuro Sugimura,et al.  Prostate cancer detection with 3 T MRI: Comparison of diffusion‐weighted imaging and dynamic contrast‐enhanced MRI in combination with T2‐weighted imaging , 2010, Journal of magnetic resonance imaging : JMRI.

[64]  J. Scheidler,et al.  Diagnosis Of Prostate Cancer In Patients With Persistently Elevated PSA And Tumor-Negative Biopsy in Ambulatory Care: Performance of MR Imaging in a Multi-Reader Environment , 2012, Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

[65]  Vladimir Bilim,et al.  Dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) is a useful modality for the precise detection and staging of early prostate cancer , 2005, The Prostate.

[66]  D. Larsimont,et al.  Localising Prostate Cancer: Comparison of Endorectal Magnetic Resonance (MR) Imaging and 3D-MR Spectroscopic Imaging with Transrectal Ultrasound-Guided Biopsy , 2011, Urologia Internationalis.

[67]  O. Geier,et al.  Routine pelvic MRI using phased-array coil for detection of extraprostatic tumour extension: accuracy and clinical significance , 2012, European Radiology.

[68]  L. Chauveinc,et al.  IRM dynamique quantitative et localisation du cancer de prostate non palpable , 2009 .

[69]  Seong Ho Park,et al.  Wash‐in rate on the basis of dynamic contrast‐enhanced MRI: Usefulness for prostate cancer detection and localization , 2005, Journal of magnetic resonance imaging : JMRI.

[70]  J. K. Kim,et al.  Prostate cancer detection on dynamic contrast-enhanced MRI: computer-aided diagnosis versus single perfusion parameter maps. , 2011, AJR. American journal of roentgenology.

[71]  H. Hricak,et al.  Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy. , 2008, Radiology.

[72]  Valeria Panebianco,et al.  Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. , 2011, European urology.

[73]  J R Griffiths,et al.  Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials. , 2003, The British journal of radiology.

[74]  A. Villers,et al.  Dynamic contrast enhanced, pelvic phased array magnetic resonance imaging of localized prostate cancer for predicting tumor volume: correlation with radical prostatectomy findings. , 2006, The Journal of urology.

[75]  Michael W Kattan,et al.  Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram. , 2007, Radiology.

[76]  Clare Allen,et al.  Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy , 2010, BJU international.

[77]  M. Brawer,et al.  Topography of neovascularity in human prostate carcinoma , 1995, Cancer.

[78]  O. Rouvière,et al.  Imaging of prostate cancer local recurrences: why and how? , 2010, European Radiology.

[79]  D P Dearnaley,et al.  Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. , 2000, Clinical radiology.

[80]  Clare Allen,et al.  How good is MRI at detecting and characterising cancer within the prostate? , 2006, European urology.

[81]  Olivier Rouvière,et al.  Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy , 2009, European Radiology.

[82]  Peter Reimer,et al.  Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines , 2013, European Radiology.